ArticleInternal and emergency medicine2020
Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.
Article in Internal and emergency medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Medications in COVID-19 patients: summarizing the current literature from an orthopaedic perspective.International orthopaedics · 2020Pooled it
- Melatonin effect on platelets and coagulation: Implications for a prophylactic indication in COVID-19.Life sciences · 2022Review
- Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation.Journal of thrombosis and thrombolysis · 2022Article
- Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry.International journal of clinical practice · 2022Article
- Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol.Drugs in context · 2022Review
- COVID-19 and Venous Thromboembolism: From Pathological Mechanisms to Clinical Management.Journal of personalized medicine · 2021Review
- PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19.Viruses · 2021Article
- Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.International journal of molecular sciences · 2021Review
- Article
- Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.European geriatric medicine · 2021Review
- Thromboprophylaxis in COVID-19 - Rationale and considerations.Advances in biological regulation · 2021Review
- Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy.International journal of biological macromolecules · 2021Article
- Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry.ACS chemical neuroscience · 2021Article
- Breakthrough venous thromboembolic events in five patients with COVID-19 on direct oral anticoagulants.Journal of clinical pharmacy and therapeutics · 2021Article
- Gene variants of coagulation related proteins that interact with SARS-CoV-2.PLoS computational biology · 2021Article
- Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.Internal and emergency medicine · 2021Article
- Hematological Abnormalities in COVID-19: A Narrative Review.The American journal of tropical medicine and hygiene · 2021Review
- DOAC in COVID-19: Yes or No?HemaSphere · 2021Article
- Coronavirus Disease 2019 (COVID-19): A Haematologist's Perspective.Acta haematologica · 2021Review
- Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19.European journal of clinical investigation · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of COVID-19 syndrome in anticoagulated patients, and especially their admission to intensive-care units with acute severe respiratory syndrome (SARS-CoV-2), expose them to specific problems related to their therapy, in addition to those associated with the acute viral infection. Patients on VKA hospitalized with SARS-CoV-2 show high instability of PT INR due to the variability of vitamin K metabolism, diet, fasting, co-medications, liver impairment, and heart failure. Patients on DOAC are exposed to under/over treatment caused by significant pharmacological interferences. In consideration of the pharmacological characteristics of oral anticoagulant drugs, the multiple pharmacological interactions due to the treatment of acute disease and the possible necessity of mechanical ventilation with hospitalization in intensive-care units, we suggest replacing oral anticoagulant therapies (VKA and DOAC) with parenteral heparin to avoid the risk of over/under treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.